Hepatitis C: Treatment of difficult to treat patients

World Journal of Hepatology

Volumn 7, Issue 15, 2015, Pages 1953-1963

  Hilgenfeldt, Eric G ^a   Schlachterman, Alex ^a   Firpi, Roberto J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cirrhosis; Direct acting antiviral; Hepatitis c virus; Human immunodeficiency virus; Treatment experienced

Indexed keywords

EID: 84938272530     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i15.1953     Document Type: Short Survey

References (59)

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293-300 [PMID:24737271 DOI: 10.7326/M13-1133]
2. WHO. Hepatitis C, Fact sheet N°164. [Updated 2014 April]. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/
3. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C. Available from: URL:http://www.hcvguidelines.org
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
5. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
6. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, Di Nubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S. Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 2014; 61: 200-209 [PMID: 24747798 DOI: 10.1016/ j.jhep.2014.03.022]
7. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
8. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.e4 [PMID:24704719 DOI: 10.1053/j.gastro.2014.03.051]
9. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM, Jacobson I, Nikitin I, Pockros PJ, Poordad F, Scott J, Lenz O, Peeters M, Sekar V, De Smedt G, Sinha R, Beumont-Mauviel M. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146:430-41.e6 [PMID: 24184810 DOI: 10.1053/j. gastro.2013.10.058]
10. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3 [PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051]
11. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
12. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, De Jesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309 DOI: 10.1016/S0140-6736(14)61036-9]
13. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]
14. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523 [PMID:24209977 DOI: 10.1016/S0140-6736(13)62121-2]
15. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]
16. Zeremski M, Martinez AD, Talal AH. Editorial commentary:Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals. Clin Infect Dis 2014; 58: 880-882 [PMID: 24336913 DOI: 10.1093/cid/cit804]
17. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450 [PMID: 15282351 DOI: 10.1056/NEJMoa040842]
18. Opravil M, Rodriguez-Torres M, Rockstroh J, Snoeck E, Chung RT, Tietz A, Torriani FJ. The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. HIV Clin Trials 2012; 13: 33-45 [PMID:22306586 DOI: 10.1310/hct1301-033]
19. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, Katlama C, Poynard T. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34: 283-287 [PMID: 11481613 DOI: 10.1053/jhep.2001.26517]
20. Deng A, Chen C, Ishizaka Y, Chen X, Sun B, Yang R. Human immunodeficiency virus type 1 Vpr increases hepatitis C virus RNA replication in cell culture. Virus Res 2014; 184: 93-102 [PMID: 24589706 DOI: 10.1016/j.virusres.2014.02.017]
21. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a longterm retrospective cohort study. Hepatology 2001; 34: 1193-1199 [PMID: 11732009 DOI: 10.1053/jhep.2001.29201]
22. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166: 1632-1641 [PMID: 16908797 DOI: 10.1001/archi nte.166.15.1632]
23. Sherman KE. Treatment of hepatitis C virus and human immunodeficiency virus co-infection. Clin Gastroenterol Hepatol 2005; 3: S118-S121 [PMID: 16234058]
24. Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis 2013; 56: 870-879 [PMID: 23090925 DOI: 10.1093/cid/cis919]
25. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16: 3041-3053 [PMID: 19689281]
26. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59: 473-485 [PMID: 18186707 DOI:10.1146/annurev.med.59.081906.081110]
27. Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, Jain MK. Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. J Viral Hepat 2013; 20: 708-714 [PMID:24010645 DOI: 10.1111/jvh.12095]
28. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging directacting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis 2014; 27: 36-45 [PMID: 24305043 DOI: 10.1097/QCO.0000000000000034]
29. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848 [PMID: 15598915 DOI: 10.1001/ jama.292.23.2839]
30. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459 [PMID: 15282352 DOI: 10.1056/NEJMoa032653]
31. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-F36 [PMID: 15316335]
32. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96 [PMID: 23685940 DOI: 10.7326/0003-4819-159-2-201307160-00654]
33. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605 [PMID: 23768747 DOI: 10.1016/S1473-3099(13)70149-X]
34. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Rodriguez-Torres M, Dieterich D. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353-361 [PMID: 25038354 DOI: 10.1001/jama.2014.7734]
35. Osinusi A, Kohli A, Marti MM, Nelson A, Zhang X, Meissner EG, Silk R, Townsend K, Pang PS, Subramanian GM, McHutchison JG, Fauci AS, Masur H, Kottilil S. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med 2014; 161: 634-638 [PMID: 25364884 DOI: 10.7326/M14-1211]
36. Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 183-197 [PMID: 15017601]
37. Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20: 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300]
38. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002; 123: 2082-2099 [PMID: 12454863 DOI:10.1053/gast.2002.1232082]
39. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146:736-743.e1 [PMID: 24262278 DOI: 10.1053/j. gastro.2013.11.007]
40. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472 [PMID: 9024300]
41. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-231 [PMID: 16298014 DOI: 10.1016/j.jhep.2005.10.013]
42. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME. Treatment of hepatitis C virus infection among people who are actively injecting drugs:a systematic review and meta-analysis. Clin Infect Dis 2013; 57 Suppl 2: S80-S89 [PMID: 23884071 DOI: 10.1093/cid/cit306]
43. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 785-789 [PMID: 9625128 DOI: 10.1111/j.1572-0241.1998.225_a. x]
44. Malek-Ahmadi P. Mood disorders associated with interferon treatment:theoretical and practical considerations. Ann Pharmacother 2001; 35: 489-495 [PMID: 11302414]
45. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 2005; 7: 391-395 [PMID: 16216160]
46. Angelino AF, Treisman GJ. Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients. Int Rev Psychiatry 2005; 17: 471-476 [PMID: 16401545 DOI:10.1080/02646830500381567]
47. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, Hamzeh FM. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-1660 [PMID: 22610658 DOI: 10.1002/ hep.25842]
48. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 2014; 59: 1246-1249 [PMID: 24493069 DOI: 10.1002/hep.27039]
49. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026]
50. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in largescale treatment access programs in developing countries. Clin Infect Dis 2014; 58: 928-936 [PMID: 24399087 DOI: 10.1093/cid/ ciu012]
51. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329-337 [PMID: 23460056 DOI:10.7326/0003-4819-158-5-201303050-00005]
52. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, de Franchis R, Almasio PL, Maisonneuve P. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 2069-2076 [PMID: 20196120 DOI: 10.1002/hep.23528]
53. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313 [PMID:11984517]
54. Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol 2013; 19: 7846-7851 [PMID: 24307778 DOI: 10.3748/wjg.v19.i44.7846]
55. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol 2013; 19: 6703-6709 [PMID: 24187444 DOI:10.3748/wjg.v19.i40.6703]
56. Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-537 [PMID: 24269472 DOI: 10.1016/j.jhep.2013.11.009]
57. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Gerber L, Nader F, Hunt S. Effects of sofosbuvirbased treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12: 1349-1359.e13 [PMID: 24316172 DOI: 10.1016/ j.cgh.2013.11.032]
58. Younossi ZM, Stepanova M, Henry L, Gane E, Jacobson IM, Lawitz E, Nelson D, Nader F, Hunt S. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014; 60: 741-747 [PMID: 24333184 DOI:10.1016/j.jhep.2013.12.006]
59. Feld JJ. The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res 2014; 105: 32-38 [PMID: 24548815 DOI: 10.1016/j.antiviral.2014.02.005]